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Abstract
Background: Association of the interleukin-23 receptor (IL23R) with inflammatory bowel disease
(IBD) has been confirmed in several populations. IL23R also associates with psoriasis, suggesting
that the gene may be an important candidate for many chronic inflammatory diseases.
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Methods: We studied association of single-nucleotide variants in IL23R with IBD in Swedish
patients, in both Crohn's disease (CD) and ulcerative colitis (UC) subsets. The same genetic
variants were also studied in Finnish patients with psoriasis or celiac disease, and in Hungarian and
Italian patients with celiac disease.
Results: Association of IL23R with IBD was replicated in our Swedish patients, and linkage and
association of the IL23R region with psoriasis was found in the Finnish population. The IL23R region
was also linked to celiac disease in Finnish families, but no association of IL23R variants with celiac
disease was found in the Finnish, Hungarian or Italian samples.
Conclusion: Our study is the first to demonstrate association of IL23R with CD and UC in
Swedish patients with IBD. It is also the first study to report linkage and association of the IL23R
region with psoriasis in the Finnish population. Importantly, this is the first report of linkage of the
IL23R region to celiac disease, a chronic inflammatory condition in which IL23R has not been
previously implicated.
Background
Association of genetic markers in the interleukin-23 recep-
tor (IL23R) gene, and the intergenic region between IL23R
and IL12RB2, with inflammatory bowel disease (IBD) was
first identified in 2006 [1]. This association has since been
replicated in both Crohn's disease (CD) and ulcerative
colitis (UC) [2-10], which are the two most frequent types
of IBD, and also in paediatric CD [11-13], psoriasis [14-
17] and ankylosing spondylitis [18]. However, no associ-
ation of IL23R with CD could be found in the Japanese
population [19]. IL23R does not appear to be associated
with systemic lupus erythematosus [20], rheumatoid
arthritis [21,22] or systemic sclerosis [23].
Our study set out to test the reported association of IL23R
with IBD and psoriasis, using Swedish and Finnish patient
materials. Given the chronic inflammatory nature of both
conditions, as well as the tissue targeted by the immune
response, we hypothesised that these same SNPs in the
IL23R region might also play a role in celiac disease- a
chronic inflammatory enteropathy caused by exposure to
dietary gluten that can also manifest as a blistering cutane-
ous disease [24]. Association of IL23R with celiac disease
was studied in three populations (Finnish, Italian and
Hungarian) due to heterogeneous allele and/or haplotype
frequencies in different population groups, where a func-
tional variant may explain a significant part of disease risk
in one population but not another.
Methods
Subject materials
Inflammatory bowel disease
Diagnosis of IBD (CD or UC) was assessed according to
established clinical criteria, including endoscopic, radiol-
ogy and histopathology data. The dataset consisted of 280
controls and 803 cases, of which 455 were UC cases and
348 were patients with CD. All patients were recruited at
the Karolinska University Hospital in Stockholm; controls
consisted of a random sample of ethnically-matched
unselected individuals.
Celiac disease
The material consisted of 3 population datasets. From Fin-
land, 260 families with celiac disease (185 multiplex fam-
ilies, 75 trios) and 165 single cases were collected at the
University of Tampere. In most patients, celiac disease was
diagnosed according to ESPGHAN criteria [25]. However,
in a small number of cases, diagnosis was based only on
the presence of disease-specific anti-endomysial antibod-
ies (ca. 1% of cases). The 292 Finnish controls have been
previously described [26]. The Hungarian dataset con-
sisted of 400 families (204 multiplex families, 196 trios),
270 cases and 270 controls; they have been previously
described [27]. The Italian dataset consisted of 139 cases
and 198 controls. Untreated celiac patients were diag-
nosed in accordance with ESPGHAN criteria [25] and
intestinal biopsies were analysed using Oberhuber's clas-
sification [28]. A subset of Finnish (10%) and Hungarian
(12%) cases were also afflicted with dermatitis herpeti-
formis (DH), the blistering cutaneous manifestation of
celiac disease [29]. Given that the genetic risk factors
underlying the gut and skin pathologies of celiac disease
are speculated to be distinct [27], linkage analyses were
performed on the total patient cohort as well as stratifying
the Finnish and Hungarian pedigrees by the presence or
absence of DH. Information regarding DH was not avail-
able for Italian patients with celiac disease or for a minor
subset of the Finnish families (27 families).
Psoriasis
The dataset consisted of 255 Finnish families (64 multi-
plex families, 191 trios), including 385 affected individu-
als, and has been described previously [30]. One psoriasis
patient from each family was randomly chosen and ana-
lysed against the Finnish control material described previ-
ously [26].BMC Medical Genetics 2009, 10:8 http://www.biomedcentral.com/1471-2350/10/8
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Table 1 gives a summary of all sample datasets in this
study. Written informed consent was obtained from all
participants in this study and local ethics committees
approved the study protocols.
Genotyping and analysis
Power calculations were performed using the online
Genetic Power Calculator [31], with power estimated to
replicate the results of Duerr et al. (2006) [1] in our TDT
and case-control materials. The prevalence of IBD was set
as 0.001, celiac disease set as 0.01 and psoriasis set as
0.02. The frequency of the rare protective allele was set as
0.07; the OR was set as 0.50 (and not 0.26 as in [1]
because this risk effect is likely to be inflated).
SNP markers in the IL23R region were chosen from Duerr
et al. (2006) [1] and were typed by MALDI-TOF analysis
on the Massarray Analyzer platform (Sequenom, San
Diego, USA). All genotyping was performed at the MAF
core facility in Karolinska Institute, Stockholm, Sweden.
Markers rs7517847 and rs1495965 were not typed due to
technical difficulties. Genotyping results, pedigree struc-
ture and affection status were imported into a BC|GENE
LIMS database (Biocomputing Platforms, Espoo, Fin-
land).
Deviations from Mendelian inheritance in the family
materials were determined with PEDCHECK 1.1 [32] and
marker genotypes were discarded in families where Men-
delian inheritance errors were detected. Mendelian inher-
itance error-rates for the pedigrees with celiac disease were
0.18% for the Finnish dataset and 0.15% for Hungarian;
the error-rate for the Finnish pedigrees with psoriasis was
0.25%. Genotyping success rates and conformity to
Hardy-Weinberg equilibrium (HWE) are shown in Addi-
tional file 1.
MERLIN 1.0.1 [33] was used to perform non-parametric
linkage analysis in the Finnish and Hungarian pedigrees
with celiac disease, as well as the Finnish pedigrees with
psoriasis. The – pairs and – exp functions were used. Hap-
loview 4.0 [34] was used to study linkage disequilibrium
(LD) patterns, estimate haplotypes and perform associa-
tion analysis. Odds ratios (OR) were calculated and two-
sided p-values reported. Genehunter (version 2.1_r5 beta)
[35] was used to perform transmission-disequilibrium
tests (TDT) in the family materials. To extract information
about association from the family materials without the
presence of linkage, we utilised a script that randomly
selected one affected individual from each family to be
used as cases in a case-control type analysis (Biocomput-
ing Platforms, Espoo, Finland).
The Cochran-Mantel-Haenszel (CMH) function in PLINK
[36] was used to perform a meta-analysis of the three
celiac disease datasets. The Breslow-Day test, estimating
Table 1: Sample sets in this study
Disease Sample set Sample size
IBD Swedish case-controls UC cases 455
CD cases 348
Controls 280
Celiac disease Finnish families 260 families (185 multiplex, 75 trios) Affected 607
Unaffected 379
Finnish case-controls Cases 165
Hungarian families 400 families (204 multiplex, 196 trios) Affected 606
Unaffected 474
Hungarian case-controls Cases 270
Controls 270
Italian case-controls Cases 139
Controls 198
Psoriasis Finnish families 255 families (64 multiplex, 191 trios) Affected 385
Unaffected 516
Controls Finnish controls (from Lappalainen et al. 2008) Controls 292
Datasets in this study. Multiplex families have more than one affected individual, trio families are comprised of father, mother, and an affected child. 
IBD indicates inflammatory bowel disease, UC indicates ulcerative colitis, and CD indicates Crohn's disease.B
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Table 2: Single-marker association of IL23R to IBD, celiac disease and psoriasis
rs100481
9*T
rs104896
29*C
rs220184
1*C
rs114658
04*G
rs112090
26*A
rs134315
1*C
rs108896
77*A
rs112090
32*A
N (cases/
controls)
p-value OR p-value OR p-value OR p-value OR p-value OR p-value OR p-value OR p-value OR
A SWE IBD 
[UC&CD]
773/280 0.004 1.38 0.006 0.76 0.054 0.002 0.42 0.003 0.45 0.014 1.30 0.088 0.130
SWE IBD 
UC
461/280 0.013 1.36 0.002 0.72 0.044 1.27 0.003 0.42 0.007 0.43 0.012 1.34 0.059 0.111
SWE IBD 
CD
337/280 0.006 1.43 0.049 0.80 0.188 0.022 0.47 0.038 0.51 0.039 1.29 0.323 0.312
B HUN CEL 610/269 0.273 0.665 0.444 0.220 0.390 0.492 0.335 0.546
FIN CEL 460/292 0.400 0.773 0.401 0.874 0.503 0.247 0.499 0.634
ITA CEL 138/194 0.803 0.324 0.390 0.753 0.778 0.570 0.334 0.491
ALL CEL 1208/750 0.524 0.865 0.846 0.279 0.677 0.399 0.849 0.424
C FIN PSOR 250/292 0.853 0.203 0.619 0.186 0.357 0.776 0.808 0.582
Association of SNPs in IL23R to inflammatory bowel disease (IBD), psoriasis (PSOR) and celiac disease (CEL) in cohorts from Sweden (SWE), Finland (FIN), Hungary (HUN) and Italy (ITA). Association to 
ulcerative colitis [UC] and Crohn's disease [CD] in the Swedish IBD (A); to celiac disease in the Finnish, Hungarian and Italian populations or combined material (B); and to psoriasis in the Finnish population 
(C). OR refers to odds ratios. Statistically significant p-values (p < 0.05) are highlighted in bold; p-values lower than 10-3 are highlighted in bold and underlined. Detailed data are shown in Additional file 3.BMC Medical Genetics 2009, 10:8 http://www.biomedcentral.com/1471-2350/10/8
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homogeneity of odds ratios, was non-significant (p >
0.05).
Results
Additional file 2 shows the linkage disequilibrium (LD)
patterns for the region surrounding IL23R and IL12RB2 in
the HapMap dataset. The position of the single-nucleotide
polymorphisms (SNPs) analysed in this study is also
shown.
IL23R and inflammatory bowel disease
The power of the IBD case-control dataset to replicate the
findings of Duerr et al. (2006) was approximately 89%.
The association of individual IL23R  markers with IBD
(UC, CD or both) is shown in Table 2A, with more detail
in Additional file 3. The strongest associations were
observed for SNPs rs11465804*G with the combined IBD
dataset (CD and UC cases; p = 0.002, OR 0.42) and
rs10489629*C with the UC cohort only (p = 0.002, OR
0.72).
Association of IL23R haplotypes with IBD is shown in
Additional file 4. The haplotype TTCTGCAA was associ-
ated with risk of IBD in Swedish patients (p = 0.009, OR
1.38), while the CCTGATCG haplotype was associated
with protection against IBD (p = 0.001, OR 0.41). It was
not informative to calculate genotype association for
rs11465804 or rs11209026 or the protective CCTGATCG
haplotype because there were too few homozygotes for
the rare protective allele.
IL23R and celiac disease
The power of the TDT analysis to replicate the results of
Duerr et al. (2006) [1] was approximately 64% in the
Finnish and 82% in the Hungarian families with celiac
disease. The power in the Finnish and Hungarian case-
control datasets was estimated at 80% and 90%, respec-
tively; it was 44% for the Italian case-control dataset.
The Finnish pedigrees with celiac disease demonstrated
linkage to the IL23R region (max lod = 3.24, p = 0.00006,
135 informative families; Table 3A) as well as significant
over-transmission of the rs10489629-rs201841-
rs11465804-rs11209026 TTTG haplotype in presence of
linkage (data not shown; 74 transmissions, 44 non-trans-
missions, p = 0.0005). When TDT without linkage was
performed, this haplotype was not significantly over-
transmitted to cases (40 transmissions, 31 non-transmis-
sions; p = 0.28). The TTTG haplotype matches with the
risk-associated alleles reported by Duerr et al. (2006) [1],
with the exception of the T allele of rs2201841. The Hun-
garian pedigrees with celiac disease showed neither signif-
icant linkage to the SNPs in the IL23R region (lod = 0.4, p
Table 3: Linkage to IL23R
A Celiac disease Samples max Z-value max lod max lod p-value
Finnish families (135) 3.19 3.24 0.00006
Hungarian families (132) 1.25 0.4 0.08
Finnish and Hungarian families (268) 3.22 3.04 0.00009
B Celiac disease-DH vs. non-DH Samples max Z-value max lod max lod p-value
Finnish DH (34) 1.87 1.03 0.015
Finnish non-DH (74) 2.53 1.71 0.0013
Hungarian DH (11) 0.14 0.01 0.4
Hungarian non-DH (121) 1.01 0.28 0.13
C Psoriasis Samples max Z-value max lod max lod p-value
Finnish families (51) 1.49 0.83 0.03
Linkage of IL23R to celiac disease and psoriasis. Max Z-value, max lod-value and max lod p-value are shown. The number of families informative for 
linkage is shown in brackets. Linkage to IL23R in A) Finnish and Hungarian celiac disease families as well as Finnish and Hungarian celiac disease 
families combined. B) Finnish and Hungarian celiac disease families with or without dermatitis herpetiformis (DH). C) Finnish psoriasis families.BMC Medical Genetics 2009, 10:8 http://www.biomedcentral.com/1471-2350/10/8
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= 0.08, 132 informative families; Table 3A) nor significant
association (data not shown).
The Finnish and Hungarian pedigrees with celiac disease
were stratified on the basis of their co-presentation of der-
matitis herpetiformis (i.e. families with DH or families
without DH) and linkage was calculated. As shown in
Table 3B, the Finnish families with DH (34 of whom were
informative for linkage) yielded a non-parametric lod-
score of 1.03 (p = 0.015), while the Finnish families with-
out DH (74 were informative for linkage) yielded a non-
parametric lodscore of 1.71 (p = 0.0013). The linkage sig-
nal (p = ns) in the Hungarian dataset came only from the
families without DH (121 families informative for link-
age). The Finnish pedigrees were also stratified into fami-
lies with one or more individuals carrying the rare
protective IBD allele (rs11209026*A) and families with-
out this allele. Families with rs11209026*A comprised
approximately 10% of the Finnish material and contrib-
uted to approximately 5% of the lodscore (p = ns, data not
shown), suggesting that this rare allele does not explain
the linkage in Finnish pedigrees with celiac disease.
One individual from each Finnish or Hungarian pedigree
was added to the single case material to increase the
power of the case-control analysis. The celiac disease case-
control datasets showed no significant association to any
of the markers at the IL23R locus, not as individual popu-
lations nor when combined for a meta-analysis (Table 2B
and Additional file 3). The celiac disease material also
demonstrated no association to the haplotypes of the
SNPs in the IL23R region (Additional file 4).
IL23R and psoriasis
The power of the Finnish psoriasis material to replicate
the results of Duerr et al. (2006) [1] was > 63%. Only 51
of the 255 families with psoriasis were informative for
linkage, yielding a lodscore of 0.83 (p = 0.03, Table 3C).
However, the role of the IL23R locus in psoriasis was sup-
ported through the family-based association tests (TDT),
in which all of the 255 families were informative. TDT
without linkage showed significant under-transmission of
the rs1343151-rs10889677-rs11209032 TCG haplotype
to patients with psoriasis (14 vs. 35 transmissions, p =
0.002; data not shown); the corresponding rs11465804-
rs11209026-rs1343151-rs10889677 TGCC haplotype
was over-transmitted to patients (64 vs. 31 transmissions,
p = 0.0007; data not shown). Importantly, the protective
TCG haplotype fits with the results of Duerr et al. (2006)
[1] and others; similarly, the risk TGCC haplotype also
corresponds with previous studies, with the exception of
the C allele of rs10889677.
An association analysis was performed by comparing
cases with psoriasis (selected from the family material)
with controls from [26]; it found no association of the
IL23R locus with psoriasis (Table 2C, and Additional files
3 and 4). Neither the rs11465804-rs11209026-
rs1343151-rs10889677 TGCC risk haplotype (0.164 fre-
quency in cases and 0.165 in controls, p = 0.96) nor the
rs1343151-rs10889677-rs11209032 TCG protective hap-
lotype (0.537 frequency in cases, 0.549 in controls, p =
0.67) were associated with psoriasis in the Finnish case-
control material.
Discussion
Pathologies that are apparently unrelated have increas-
ingly been shown to share common genetic risk factors,
such as celiac disease and schizophrenia in terms of
MYO9B [37,38]. Conditions that are driven by an overac-
tive/inappropriate immune response can be more easily
envisaged to share common factors that contribute to
their chronic inflammatory state. It is for this reason that
we have examined IBD, psoriasis and celiac disease in this
study.
Our study is the first to show genetic association of IL23R
with IBD in the Swedish population. In particular, we
found strong association of the marker rs1004819 with
Crohn's disease, thereby replicating the association
reported in the German population [4]. In the German
study, association was only demonstrated with this partic-
ular SNP, which is located at the junction of two linkage
disequilibrium (LD) blocks (Additional file 2). These
findings raise the possibility of another polymorphism in
the LD block upstream of the rs1004819 marker that
affects susceptibility to IBD. Such a polymorphism is
envisaged to act independently of rs11209026 or the var-
iants immediately surrounding it.
The risk and protective haplotypes associated with
Crohn's disease and ulcerative colitis in the Swedish pop-
ulation were identical to those found in the first reported
association of IL23R with IBD [1]. However, IL23R was
not involved in susceptibility to ulcerative colitis in the
Finnish population [26]. These findings are interesting
given that the Swedish and Finnish are neighbouring pop-
ulations and they also share association of Crohn's dis-
ease to the same genetic variants and risk/protective
haplotypes at this locus. The differences in Swedish and
Finnish cases with ulcerative colitis may reflect genetic
variation in the two populations at other IBD risk loci.
The IL23R region demonstrated linkage to psoriasis in the
Finnish pedigrees, suggesting that the locus is involved in
this inflammatory skin disorder. Linkage of this gene
region has not previously been shown to psoriasis in the
Finnish population. Importantly, in support of our link-
age results, association of IL23R with psoriasis was con-
firmed in the Finnish case-controls, demonstrating under-BMC Medical Genetics 2009, 10:8 http://www.biomedcentral.com/1471-2350/10/8
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transmission of previously reported protective variants
and over-transmission of the corresponding risk variants.
Other studies have reported association to the
rs11209026 (Arg381Gln) polymorphism in IL23R, as
well as to polymorphisms in IL12B, which encodes the β-
chain of the IL23 cytokine [14,15,39]. Taken together,
these collective findings suggest that polymorphisms in
several components of the IL23/IL23R-pathway may be
important for susceptibility to psoriasis. Indeed, anti-
IL12/IL23 antibody treatment ameliorates the symptoms
of psoriasis [40], further supporting the importance of
multiple components this pathway in the disease.
The gene region containing IL23R was strongly linked to
celiac disease in the Finnish families, but did not reach
statistical significance in the Hungarian pedigrees- a result
that perhaps reflects the heterogeneity of the two popula-
tions. The discrepancy between the populations could
raise questions about the biological relevance of the link-
age findings, but large differences in allele and haplotype
frequencies between populations have been reported by
others, suggesting that the effect of the same genetic risk
variant may vary considerably across different popula-
tions. Indeed, it is thought that some of the celiac disease
risk loci for the Finnish and Hungarian populations are
distinct [27]. Therefore, it is possible that the IL23R region
is linked to celiac disease in the Finnish population but
not the Hungarian. Future replication studies may help to
determine whether the region is truly linked to celiac dis-
ease.
Interestingly, stratification of the celiac disease dataset by
the co-occurrence of dermatitis herpetiformis indicated
that linkage was independent of celiac disease sub-pheno-
type. Despite the linkage results in the Finnish families,
the case-control material of all three populations (Finn-
ish, Hungarian and Italian) showed no association of
IL23R with celiac disease, and family-based association
tests supported the lack of association of these markers.
The linkage of celiac disease to the IL23R region may be
due to other genetic factors than the ones reported by
Duerr et al. (2006) [1]. In support of this, stratification of
the celiac disease dataset by the A-allele of rs11209026
indicated that linkage in the Finnish families with celiac
disease was independent of this variant. Intriguingly, this
allele A was recently found to be associated with risk
instead of protection from both celiac disease and multi-
ple sclerosis in the Spanish population [41]. These find-
ings in the Spanish population suggest that, if rs11209026
is the primary functional variant, IL23R would play an
opposite role in celiac disease and multiple sclerosis com-
pared to IBD and psoriasis. Perhaps more likely, is that
these opposite alleles are simply tagging distinct haplo-
types carrying the real primary risk variants.
Variants in the LD block upstream of IL23R  or in the
downstream LD block covering IL12RB2, may explain the
linkage to celiac disease in the Finnish population.
IL12RB2 and IL12RB1 encode for the two chains of the
IL12 receptor. The IL23 receptor shares the protein
encoded by IL12RB1 but also requires IL23R. Similarly,
the ligands bound by these receptors, IL12 and IL23, are
composed by shared subunits: IL12 is encoded by IL12A
and IL12B, while IL23 is encoded by IL23A and IL12B.
Interestingly, celiac disease is associated with IL12A
[42,43] and thereby differs from IBD and psoriasis, where
IL12B variants have shown risk effect. Hence, the IL12A
association and the proximity of IL12RB2 to IL23R (which
appears linked to celiac disease), suggest that the genes of
the IL12 pathway are particularly interesting to investigate
in future genetic studies of celiac disease. Independent
associations of psoriasis and psoriatic arthritis with both
IL23R and a SNP 4 kb upstream of IL12RB2 [39], indicate
that extended studies in this gene cluster would be rele-
vant to other chronic inflammatory diseases as well.
IL23R gene variants have now been repeatedly implicated
in a number of inflammatory diseases and perhaps sug-
gest that these pathologies are mediated by the Th17 path-
way. Despite many studies finding association of these
diseases with the IL23R region, few have reported func-
tional evidence for the involvement of IL23R variants. It is
known that the rs11209026 SNP results in an amino acid
change in the intracellular domain of the IL23 receptor
and thus the polymorphism may affect the downstream
signalling of the receptor. However, our preliminary func-
tional studies suggest that the rs11209026 genotype does
not significantly affect expression of the IL23 receptor on
peripheral blood mononuclear cells of healthy donors
(data not shown). Nevertheless, it cannot be excluded that
other factors carried on the protective haplotype tagged by
rs11209026 could have an effect on expression levels of
IL23R, or on the stability or alternative splicing of mRNA.
It is apparent that the variants in the IL23R region exam-
ined in this study are not associated with celiac disease.
However, it is equally clear that some factor in this gene
region affects susceptibility to celiac disease. The region
needs to be investigated further to identify the precise
genetic variants that contribute to celiac disease. Future
studies employing a tagging strategy of the whole IL12RB2
gene may be useful in IBD, psoriasis and celiac disease.
Such a strategy may be able to elucidate the disease-caus-
ing variants in celiac disease, as well as identifying addi-
tional variants that modify the risk of IBD and psoriasis.
Conclusion
Our study is the first to report association of IL23R with
Crohn's disease and ulcerative colitis in Swedish patients
with IBD. It is also the first study to demonstrate linkageBMC Medical Genetics 2009, 10:8 http://www.biomedcentral.com/1471-2350/10/8
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and association of the IL23R region with psoriasis in the
Finnish population. But perhaps the most interesting
novel finding is that of linkage of the IL23R region to
celiac disease. It remains to be elucidated whether IL23R,
IL12RB2 or another gene at 1p31 confers risk to celiac dis-
ease.
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